<a href="https://laohu8.com/S/01255">Tata Health</a> Reports 30.5% Revenue Drop for H1 2024, Loss Narrows to HK$5.13 Million, EPS at HK$0.02
Tata Health International Holdings Limited announced its interim results for the six months ended June 30, 2024. The company reported a revenue of HK$72.3 million, down from HK$104.1 million in the same period in 2023. The gross profit for the period also decreased to HK$55.4 million from HK$85.2 million in the previous year. The company reported a loss before taxation of HK$5.1 million, an improvement compared to the loss of HK$14.3 million reported in the same period last year. The loss attributable to owners of the company was HK$5.1 million, compared to HK$12.3 million in 2023. The gross profit margin decreased from 81.9% to 76.6%, and the loss margin attributable to owners improved from 11.8% to 7.1%. The revenue from the sales of goods was primarily from footwear products, totaling HK$72.3 million, compared to HK$100.7 million in 2023. The sales were mainly through retail channels, which contributed HK$70.3 million, and wholesale channels, which contributed HK$2 million. The company did not report any revenue from online medical services or financial services during the six months ended June 30, 2024. There was no reported outlook or guidance for future periods included in the announcement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tata Health International Holdings Limited published the original content used to generate this news brief on September 22, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.